Replies to post #158 on Immatics NV (IMTX)

[FACT-MASTER]

I concur with all of your thoughts as well.

I'm actually surprised we have not heard anything yet on IMA203 trial progress / FDA approval for path forward.

I noticed Amgen received FDA approval for a Bi-specific T-engager, that was a surprise as i wasn't aware that Amgen was involved with T-TCR tech.
Bodes well for Immatics, imo

Here is the story on Amgen:

https://finance.yahoo.com/news/fda-approves-imdelltra-tarlatamab-dlle-224500427.html

Something appears to be up today!

IMA402 was updated as of May 24 - no major changes, locations etc.

https://classic.clinicaltrials.gov/ct2/history/NCT05958121?A=1&B=13&C=merged#StudyPageTop

[FACT-MASTER]

As an additional note, Amgen's Imdelltra had also received "accelerated approval" status, however i have not researched the specifics of when and under what program.

Would be worth to investigate, imo

https://finance.yahoo.com/news/fda-approves-imdelltra-tarlatamab-dlle-224500427.html